Stock Financial Ratios, Dividends, Split History

QTNT / Quotient Limited financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price7.14
Volume347,500.00
Market Cap ($M)177.31
Enterprise Value ($M)256.56
Book Value ($M)-14.63
Book Value / Share-0.32
Price / Book-7.36
NCAV ($M)-86.43
NCAV / Share-1.89
Price / NCAV-3.78
Share Statistics
Common Shares Outstanding 45,755,978
Common Stock Shares Outstanding 45,646,424
Temporary Equity Shares Outstanding Including Debt 666,665
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.19
Return on Assets (ROA)-0.75
Return on Equity (ROE)3.42
Balance Sheet (mrq) ($M)
Assets123.84
Liabilities138.47
Quick Ratio1.32
Current Ratio1.92
Income Statement (mra) ($M)
Other Sales Revenue Net819,000.00
Revenues24,732,000.00
Sales Revenue Goods Net23,913,000.00
Operating Income-69.99
Net Income-82.34
Earnings Per Share Basic And Diluted-2.02
Cash Flow Statement (mra) ($M)
Cash From Operations-68.42
Cash from Investing3.34
Cash from Financing-68.42
Identifiers and Descriptors
CUSIPG73268107
Central Index Key (CIK)1596946

Split History

Stock splits are used by Quotient Limited to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Week 25 Breakout Forecast: Short-Term Picks To Give You An Edge

3h seekingalpha
Publishing 2 of the 8 new Week 25 breakout stocks that are available only to subscribers with better than 10% short-term upside potential. (5-0)

Quotient Limited's (QTNT) CEO Franz Walt on Q4 2018 Results - Earnings Call Transcript

2018-05-29 seekingalpha
Greetings, and welcome to the Quotient Limited Fourth Quarter and Fiscal Year 2018 Financial Results Conference Call. As a reminder, this conference is being recorded. (2-0)

Quotient Limited: Buy This Industry Disruptor

2018-05-21 seekingalpha
Quotient Limited (QTNT) is breaking out higher due to positive developments in its MosaiQ platform. The company successfully finished a verification/validation phase for its platform, and is on its way to commercialization in the large, highly developed reagent market. Its share price has broken a multi-year downtrend on the news, and looks to advance further in coming quarters. I am buying stock in this name as its disruptive technology looks to fuel more investor optimism. (2-2)

Week 19 Breakout Forecast: Short-Term Picks To Give You An Edge

2018-05-06 seekingalpha
Publishing 2 of the 8 new Week 19 breakout stocks that are available only to subscribers with better than 10% short-term upside potential. (27-1)

BRIEF-Quotient Announces Retirement Of CEO Paul Cowan

2018-03-26 reuters
* QUOTIENT LIMITED ANNOUNCES RETIREMENT OF PAUL COWAN, CHAIRMAN AND CHIEF EXECUTIVE OFFICER; FRANZ WALT NAMED AS INTERIM CHIEF EXECUTIVE OFFICER (2-0)

CUSIP: G73268107